secwatch.observer — SEC 8-K summary
======================================

Issuer:     Evolus, Inc. (EOLS)
CIK:        0001570562
Form:       8-K
Filed at:   2023-05-09T23:59:59+00:00
Accession:  0001570562-23-000068
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 1.01, 2.02, 2.03, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Evolus Q1 revenue up 23% to $41.7M; enters filler market; raises 2028 outlook to $700M
--------------------------------------------------------------------------------

- Q1 net revenue $41.7M, +23% YoY; reaffirms FY2023 guidance of $180-190M.
- Signs exclusive U.S. distribution deal with Symatese for 5 dermal fillers (Evolysse); first approval expected 1H2025.
- Raises 2028 revenue outlook to $700M (from $500M), implying ~29% CAGR from combined Jeuveau and filler line.
- Amends Pharmakon debt to draw $50M second tranche in two installments ($25M May 2023, $25M Dec 2023); extends interest-only period 12 months.
- CEO David Moatazedi awarded 560,000 performance RSUs; vests if stock price ≥$30 (40%) or ≥$50 (60%) within 5 years.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1570562/000157056223000068/0001570562-23-000068-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1570562/000157056223000068/eols-20230508.htm
  HTML page:      https://secwatch.observer/filing/0001570562-23-000068

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer